Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Università di Perugia
Perugia, ItaliaPublicaciones en colaboración con investigadores/as de Università di Perugia (34)
2024
-
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
ESMO Open, Vol. 9, Núm. 2
-
Development and external validation of the 'Global Surgical-Site Infection' (GloSSI) predictive model in adult patients undergoing gastrointestinal surgery
British Journal of Surgery, Vol. 111, Núm. 6
-
Is tranexamic acid appropriate for all patients undergoing high-risk surgery?
Current Opinion in Critical Care
-
Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal study
Spanish Journal of Psychiatry and Mental Health
-
Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators
Journal of Prevention of Alzheimer's Disease
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
-
Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network
European Journal of Cancer, Vol. 196
2023
-
Association of Intima-Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta-Analysis of 20 Prospective Studies
Journal of the American Heart Association, Vol. 12, Núm. 12, pp. e027657
-
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221
-
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Annals of Oncology, Vol. 34, Núm. 5, pp. 452-467
2022
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
-
The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres
European Journal of Cancer, Vol. 177, pp. 72-79
2021
-
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
-
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Neurology, Vol. 97, Núm. 14, pp. E1367-E1381
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Pressure injury prediction models for critically-ill patients should consider both the case-mix and local factors
Intensive and Critical Care Nursing
-
Survival and quality of life after early discharge in low-risk pulmonary embolism
European Respiratory Journal, Vol. 57, Núm. 2
-
Who Will Take Care of Me? The Future of Human Resources in Anaesthesiology, Critical Care, and Emergency Medicine in Europe
Research Anthology on Cross-Industry Challenges of Industry 4.0 (IGI Global), pp. 752-766
2020
-
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: An international multicentre single-arm clinical trial
European Heart Journal, Vol. 41, Núm. 4, pp. 509-518